Aptose Biosciences Inc. Issues Press Release – Form 8-K Filing

Aptose Biosciences Inc., a biotechnology company headquartered in Canada and listed on the Nasdaq Stock Market under the symbol APTO, recently made a key disclosure in a Form 8-K filing to the United States Securities and Exchange Commission.

The current report, dated December 12, 2024, highlighted that Aptose Biosciences Inc. released a press release on the same day. The press release, detailed as Exhibit 99.1 in the filing, can provide further insights into the company’s recent developments. As per the disclosure, the information contained in the press release is not considered “filed” under the Securities Exchange Act of 1934, nor is it incorporated by reference in any filings under the Securities Act of 1933 or the Exchange Act unless specifically referenced in such filings.

In addition to the press release, the Form 8-K filing included an Interactive Data File (Exhibit 104) embedded within the Inline XBRL document.

The signing of the report was done on behalf of Aptose Biosciences Inc. by William G. Rice, Ph.D., who serves as the President and Chief Executive Officer of the company.

Investors and stakeholders are encouraged to refer to the full Form 8-K filing on the SEC’s website for comprehensive details regarding Aptose Biosciences Inc.’s recent announcements and the press release issued on December 12, 2024.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Aptose Biosciences’s 8K filing here.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.